Major study tests drug combo to keep breast cancer from coming back

NCT ID NCT06930859

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is observing patients in Russia to see if adding the drug ribociclib to standard hormone therapy is more effective at preventing breast cancer from returning after initial treatment. It will follow over 2,700 patients who have had surgery for a specific type of breast cancer. The goal is to compare outcomes for patients taking the drug combination against those taking hormone therapy alone in real-world medical practice.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

Novartis Investigative Site
RECRUITING

Kaluga, Russia, 248007, Russia
Novartis Investigative Site
RECRUITING

Ryazan, Russia, 390011, Russia
Novartis Investigative Site
RECRUITING

Surgut, Tymen Area, 628402, Russia
Novartis Investigative Site
RECRUITING

Arkhangelsk, 163045, Russia
Novartis Investigative Site
RECRUITING

Barnaul, 656045, Russia
Novartis Investigative Site
RECRUITING

Irkutsk, 664035, Russia
Novartis Investigative Site
RECRUITING

Ivanovo, 153040, Russia
Novartis Investigative Site
RECRUITING

Izhevsk, 426009, Russia
Novartis Investigative Site
RECRUITING

Kemerovo, 650036, Russia
Novartis Investigative Site
RECRUITING

Khabarovsk, 680042, Russia
Novartis Investigative Site
RECRUITING

Khimky, 121552, Russia
Novartis Investigative Site
RECRUITING

Kirov, 610021, Russia
Novartis Investigative Site
RECRUITING

Krasnoyarsk, 660022, Russia
Novartis Investigative Site
RECRUITING

Moscow, 115304, Russia
Novartis Investigative Site
RECRUITING

Moscow, 115522, Russia
Novartis Investigative Site
RECRUITING

Moscow, 125284, Russia
Novartis Investigative Site
RECRUITING

Moscow, 129110, Russia
Novartis Investigative Site
RECRUITING

Moscow Region Balas, 143900, Russia
Novartis Investigative Site
RECRUITING

Perm, 614066, Russia
Novartis Investigative Site
RECRUITING

Pyatigorsk, 357502, Russia
Novartis Investigative Site
RECRUITING

Saint Petersburg, 194017, Russia
Novartis Investigative Site
RECRUITING

Saint Petersburg, 194291, Russia
Novartis Investigative Site
RECRUITING

Saint Petersburg, 197758, Russia
Novartis Investigative Site
RECRUITING

Saransk, 430032, Russia
Novartis Investigative Site
RECRUITING

Tver', 170008, Russia
Novartis Investigative Site
RECRUITING

Tyumen, 625023, Russia
Novartis Investigative Site
RECRUITING

Ufa, 450054, Russia
Novartis Investigative Site
RECRUITING

Vladikavkaz, 362002, Russia
Novartis Investigative Site
RECRUITING

Vladivostok, 690105, Russia
Novartis Investigative Site
RECRUITING

Volgograd, 400138, Russia
Novartis Investigative Site
RECRUITING

Voronezh, 394036, Russia
Novartis Investigative Site
RECRUITING

Yaroslavl, 150054, Russia
Novartis Investigative Site
RECRUITING

Yekaterinburg, 620036, Russia
Novartis Investigative Site
RECRUITING

Yuzhno-Sakhalinsk, 693010, Russia

Conditions

Explore the condition pages connected to this study.

BREAST CANCER